Related Experiment Video
Updated: Jun 8, 2026
12:37
Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)
Published on: September 11, 2012
Adjuvant therapy for colon cancer.
1Colorectal Oncology Section, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. saltzl@mskcc.org
Surgical Oncology Clinics of North America
|October 2, 2010
Summary
Adjuvant treatments aim to eliminate microscopic disease after surgery. While Stage III colon cancer patients benefit from chemotherapy, Stage I and II patients have good prognoses, with limited evidence for adjuvant chemotherapy in Stage II.
Area of Science:
- Oncology
- Surgical Oncology
- Gastrointestinal Oncology
Background:
- Post-operative residual microscopic disease, not the primary tumor, poses a risk of mortality.
- Adjuvant therapies aim to eradicate undetectable metastatic disease after surgical resection.
Purpose of the Study:
- To evaluate the role and indications for adjuvant treatment in colorectal cancer.
- To clarify the contentious use of adjuvant chemotherapy in Stage II colon cancer.
- To define the standard of care for Stage III colorectal cancer.
Main Methods:
- Review of current clinical evidence and treatment guidelines for adjuvant therapy in colorectal cancer.
- Analysis of prognostic factors and recurrence risks across different disease stages.
- Discussion of decision-making complexities for adjuvant chemotherapy in Stage II disease.
Main Results:
- Stage I colorectal cancer generally has an excellent prognosis without adjuvant chemotherapy.
- Stage II colon cancer presents a complex scenario for adjuvant chemotherapy decisions due to good prognosis post-surgery alone.
- Stage III colorectal cancer (TanyN₁₋₂M₀) patients are at higher risk of recurrence and typically receive adjuvant chemotherapy.
Conclusions:
- Adjuvant chemotherapy is routinely indicated for Stage III colorectal cancer.
- The use of adjuvant chemotherapy for Stage II colon cancer remains a complex and debated topic.
- Current evidence does not strongly support adjuvant chemotherapy for Stage I colorectal cancer.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...